Anxiety Depression, Depression, Obsessive-Compulsive Disorder
Conditions
Keywords
TMS
Brief summary
In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.
Interventions
DEVICENeuroStar Advanced TMS Therapy System
non-invasive brain stimulation device
Sponsors
Neuronetics
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
5 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
* Male or female reported in database and not an invalid entry * Age reported and not an invalid entry * Treatment date of November 01, 2008 or later.
Exclusion criteria
• Incomplete information on treatment parameters
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in clinical assessment score from baseline to post-treatment | 8 weeks | real-world efficacy of NeuroStar TMS in reducing patients' symptoms, reduction in clinical assessment score like PHQ-9 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Age at baseline and its correlation to change in score post treatment | 8 weeks | Determine the patient characteristics like age that are associated with clinical outcomes- PHQ-9 following NeuroStar TMS |
Countries
United States
Contacts
CONTACTNeha Goyal
CONTACTEleanor Cole, PhD
STUDY_DIRECTOREleanor Cole, PhD
Neuronetics
Outcome results
None listed